Formulation: A crystalline solid
Formal Name: (9R,9'R)-5,5'-bis(β-D-glucopyranosyloxy)-9,9',10,10'-tetrahydro-4,4'-dihydroxy-10,10'-dioxo-[9,9'-bianthracene]-2,2'-dicarboxylic acid
Purity: ≥98%
Formula Markup: C42H38O20
Formula Weight: 862,7
Shelf life (days): 1460
CAS Number: 81-27-6
Notes: Sennoside A is a dianthrone glycoside with laxative and gastroprotective activities.{43196,43197} Ex vivo, sennoside A (30 mg/kg) increases the amplitude of distal colon contractions in circular and longitudinal muscle and decreases the amplitude of proximal colon contractions in circular muscle in mice.{43196} Sennoside A (100 mg/kg, oral) increases the gastric emptying rate by 71.1% compared to control and increases the intestinal transport rate of a charcoal meal from 61.2 to 81.1% in mice.{43197} It increases the concentration of prostaglandin E2 (PGE2; Item No. 14010) in AGS gastric cells in a dose-dependent manner in vitro. Intraduodenal administration of sennoside A (100 mg/kg) increases gastric juice pH and decreases gastric juice secretion volume and total acid output in pylorus-ligated rats. It also reduces lesion indices by 43.1 and 36% in HCl/ethanol-induced gastritis and indomethacin-induced gastric ulcer rat models, respectively, when administered at a dose of 100 mg/kg. Sennoside A is also a non-competitive inhibitor of bovine serum monoamine oxidase in vitro (IC50 = 17 µM).{43198} Formulations containing sennoside A have been used to treat constipation and to aid in evacuation of the bowel prior to surgery or invasive colonic or rectal examinations.